SLC5A2 and diabetes mellitus: Notably, the EMPEROR-Preserved study recently reported that the SGLT2 inhibitor, empagliflozin, can reduce HF hospitalization and cardiovascular death in HFpEF patients with and without diabetes by ~ 21% [9].